


# TOWARDS A BETTER USAGE OF OXYTETRACYCLINE IN THE EGG INDUSTRY

Micaela Miyauchi<sup>1</sup>, Marie-Lou Gaucher<sup>1</sup>, Francis Beaudry<sup>1</sup>, William Thériault<sup>1</sup>, Mohamed Rhouma<sup>1</sup>

<sup>1</sup> Centre de recherche en infectiologie porcine et avicole (CRIPA), Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada.

**35,6 MILLIONS**

of laying hens in Canada



**10 BILLION**

eggs produced annually in the country



## THREATENED BY:

Avian pathogenic *Escherichia coli* (APEC)



MORTALITY



PRODUCTION

## OXYTETRACYCLINE (OTC)

Used for the treatment of APEC infections


**BUT!!!**

INCREASE IN ANTIMICROBIAL-RESISTANT APEC

NO OPTIMIZATION OF OTC DOSAGE REGIMENS SINCE 1960

## MY MISSION:

DEVELOP AN *IN VIVO* MODEL OF THE DISEASE



**TO**



1) Define optimal dose/duration treatment with OTC to reduce treatment failures



2) Reduce the withdrawal time of eggs for human consumption